ILRUN

Summary

ILRUN (inflammation and lipid regulator with UBA-like and NBR1-like domains, HGNC:21215) is a protein-coding gene on chromosome 6p21.31, encoding Protein ILRUN (Q9H6K1). Negative regulator of innate antiviral response.

This gene encodes a protein with N-terminal ubiquitin-associated (UBA)-like and central neighbor of BRCA1 gene 1 (NBR1)-like domains. The protein acts an inhibitor of antiviral and proinflammatory cytokine transcription and as a regulator of the renin-angiotensin-aldosterone system (RAAS).

Source: NCBI Gene 64771 — RefSeq curated summary.

At a glance

• GWAS associations: 75
• Clinical variants (ClinVar): 6 total
• MANE Select transcript: NM_024294

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21215
Approved symbol	ILRUN
Name	inflammation and lipid regulator with UBA-like and NBR1-like domains
Location	6p21.31
Locus type	gene with protein product
Status	Approved
Aliases	FLJ22195, dJ391O22.4
Ensembl gene	ENSG00000196821
Ensembl biotype	protein_coding
OMIM	612217
Entrez	64771

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000374021, ENST00000374023, ENST00000374026, ENST00000857868, ENST00000857869, ENST00000857870, ENST00000857871, ENST00000943487

RefSeq mRNA: 2 — MANE Select: NM_024294 NM_022758, NM_024294

CCDS: CCDS4795, CCDS4796

Canonical transcript exons

ENST00000374023 — 5 exons

Exon	Start	End
ENSE00000929510	34646601	34646798
ENSE00001429798	34606555	34606904
ENSE00001462187	34696446	34696767
ENSE00001462194	34587288	34590600
ENSE00003685125	34654625	34654779

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 97.89.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.8901 / max 204.1649, expressed in 1788 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
73262	6.7520	1735
73264	1.8309	930
73265	0.4292	218
73261	0.3801	158
73260	0.2605	107
73263	0.1662	67
73259	0.0711	39

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gastrocnemius	UBERON:0001388	97.89	gold quality
tendon of biceps brachii	UBERON:0008188	97.74	gold quality
muscle of leg	UBERON:0001383	97.66	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.62	gold quality
medial globus pallidus	UBERON:0002477	96.53	gold quality
buccal mucosa cell	CL:0002336	96.45	gold quality
muscle organ	UBERON:0001630	96.20	gold quality
islet of Langerhans	UBERON:0000006	96.17	gold quality
apex of heart	UBERON:0002098	96.17	gold quality
right testis	UBERON:0004534	95.89	gold quality
left testis	UBERON:0004533	95.77	gold quality
globus pallidus	UBERON:0001875	95.56	gold quality
heart left ventricle	UBERON:0002084	95.17	gold quality
cerebellar hemisphere	UBERON:0002245	95.09	gold quality
amniotic fluid	UBERON:0000173	95.07	gold quality
right frontal lobe	UBERON:0002810	95.06	gold quality
cerebellar cortex	UBERON:0002129	95.04	gold quality
cardiac ventricle	UBERON:0002082	95.02	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.90	gold quality
right atrium auricular region	UBERON:0006631	94.79	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.69	gold quality
testis	UBERON:0000473	94.60	gold quality
tendon	UBERON:0000043	94.57	gold quality
lower esophagus	UBERON:0013473	94.37	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.36	gold quality
prefrontal cortex	UBERON:0000451	94.33	gold quality
right lobe of liver	UBERON:0001114	94.28	gold quality
heart	UBERON:0000948	94.15	gold quality
cardiac atrium	UBERON:0002081	94.11	gold quality
skeletal muscle tissue	UBERON:0001134	94.09	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.65
E-GEOD-110499	no	331.36

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

208 targeting ILRUN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-8485	100.00	77.57	4731
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062

Literature-anchored findings (GeneRIF, showing 9)

• Ethanol, but not acetaldehyde, inhibited PPAR-beta transactivation. (PMID:18003597)
• DSCR2 was found to interact with PPARbeta and to inhibit it. (PMID:18793612)
• up-regulated expression by repetitive low-grade oxidative stress through p38MAPK or NF-kappaB pathways (PMID:19059477)
• C6orf106 promotes invasion in NSCLC cells. Finally, C6orf106 upregulates vimentin, and downregulates E-cadherin and P120ctn. (PMID:25736925)
• High C6orf106 expression was significantly correlated with lymph node metastasis in triple-negative breast cancer. (PMID:25953261)
• High C6orf106 expression is associated with innate antiviral response. (PMID:29802199)
• C6orf106 facilitates invasion and proliferation of pancreatic cancer cells, likely via activating ERK-P90RSK signaling pathway. (PMID:30311108)
• we detected a novel obesity and BMI-associated locus at PKHD1 and novel variants driving associations at previously established signals (e.g. rs205262 at the SNRPC/C6orf106 locus and rs112446794 at the PRDM6-CEP120 locus). (PMID:30677029)
• ILRUN Downregulates ACE2 Expression and Blocks Infection of Human Cells by SARS-CoV-2. (PMID:33963054)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ilrun	ENSDARG00000078075
mus_musculus	Ilrun	ENSMUSG00000056692
rattus_norvegicus	Ilrun	ENSRNOG00000038883

Protein

Protein identifiers

Protein ILRUN — Q9H6K1 (reviewed: Q9H6K1)

Alternative names: Inflammation and lipid regulator with UBA-like and NBR1-like domains protein

All UniProt accessions (2): Q9H6K1, Q5TH58

UniProt curated annotations — full annotation on UniProt →

Function. Negative regulator of innate antiviral response. Blocks IRF3-dependent cytokine production such as IFNA, IFNB and TNF. Interacts with IRF3 and inhibits IRF3 recruitment to type I IFN promoter sequences while also reducing nuclear levels of the coactivators EP300 and CREBBP.

Subunit / interactions. Interacts with IRF3; the interaction inhibits IRF3 binding to its DNA consensus sequence.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed in lung (at protein level).

Induction. Expression is increased in presence of dsRNA such as poly(I:C).

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H6K1-1	1	yes
Q9H6K1-2	2

RefSeq proteins (2): NP_073595, NP_077270* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009060	UBA-like_sf	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR032350	Nbr1_FW	Domain
IPR039517	C6orf106_UBA-like	Domain

Pfam: PF14555, PF16158

UniProt features (17 total): strand 8, modified residue 3, compositionally biased region 2, chain 1, region of interest 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6VHI	X-RAY DIFFRACTION	2.46

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H6K1-F1	71.26	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 215, 222, 272

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 233 (showing top): ELVIDGE_HYPOXIA_DN, MODULE_255, GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, AAGCCAT_MIR135A_MIR135B, MODULE_317, GOBP_NEGATIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, TGACCTY_ERR1_Q2, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_MACROAUTOPHAGY, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_BIOTIC_STIMULUS, CAGCAGG_MIR370, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_NEGATIVE_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM

GO Biological Process (8): macroautophagy (GO:0016236), negative regulation of type I interferon production (GO:0032480), negative regulation of tumor necrosis factor production (GO:0032720), negative regulation of DNA binding (GO:0043392), innate immune response (GO:0045087), negative regulation of defense response to virus (GO:0050687), negative regulation of protein localization to nucleus (GO:1900181), immune system process (GO:0002376)

GO Molecular Function (2): ubiquitin binding (GO:0043130), protein binding (GO:0005515)

GO Cellular Component (6): phagophore assembly site (GO:0000407), nucleus (GO:0005634), cytoplasm (GO:0005737), centrosome (GO:0005813), cytosol (GO:0005829), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cytoplasm	2
autophagosome assembly	1
autophagy	1
negative regulation of cytokine production	1
regulation of type I interferon production	1
type I interferon production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
negative regulation of tumor necrosis factor superfamily cytokine production	1
DNA binding	1
negative regulation of binding	1
regulation of DNA binding	1
immune response	1
defense response to symbiont	1
negative regulation of response to biotic stimulus	1
negative regulation of defense response	1
negative regulation of response to external stimulus	1
regulation of defense response to virus	1
defense response to virus	1
protein localization to nucleus	1
regulation of protein localization to nucleus	1
negative regulation of protein localization	1
biological_process	1
ubiquitin-like protein binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
centriole	1
microtubule organizing center	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

566 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ILRUN	BLTP3A	Q6BDS2	588
ILRUN	A0A2U3TZT1	A0A2U3TZT1	575
ILRUN	NUDT3	O95989	542
ILRUN	SPDEF	O95238	476
ILRUN	C17orf67	Q0P5P2	446
ILRUN	SNRPC	P09234	428
ILRUN	RSRC2	Q7L4I2	401
ILRUN	TDP2	O95551	381
ILRUN	PACSIN1	Q9BY11	377
ILRUN	SCMH1	Q96GD3	370
ILRUN	C3orf38	Q5JPI3	368
ILRUN	ZBTB38	Q8NAP3	356
ILRUN	ZNF704	Q6ZNC4	350
ILRUN	DYM	Q7RTS9	349
ILRUN	FAM219B	Q5XKK7	349

IntAct

14 interactions, top by confidence:

A	B	Type	Score
HSPA8	GAK	psi-mi:“MI:0914”(association)	0.760
MCOLN1	MCOLN2	psi-mi:“MI:0914”(association)	0.530
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530
ILRUN	RPSA	psi-mi:“MI:0915”(physical association)	0.370
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
HSPBP1	HGS	psi-mi:“MI:0914”(association)	0.350
STK26		psi-mi:“MI:0914”(association)	0.350
hspa1a_hspa1b_human-1	SHTN1	psi-mi:“MI:0914”(association)	0.350
HSPA8	SBNO1	psi-mi:“MI:0914”(association)	0.350
HSPA8	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
ILRUN	UBA1	psi-mi:“MI:0220”(ubiquitination reaction)	0.000

BioGRID (19): C6orf106 (Biochemical Activity), C6orf106 (Affinity Capture-MS), C6orf106 (Biochemical Activity), C6orf106 (Affinity Capture-MS), C6orf106 (Affinity Capture-MS), C6orf106 (Affinity Capture-RNA), C6orf106 (Affinity Capture-RNA), UBC (Affinity Capture-Western), PPARA (Affinity Capture-Western), PPARG (Affinity Capture-Western), C6orf106 (Affinity Capture-MS), C6orf106 (Affinity Capture-MS), C6orf106 (Affinity Capture-MS), C6orf106 (Affinity Capture-MS), C6orf106 (Affinity Capture-MS)

ESM2 similar proteins: A0A8M1NHK4, A3KFF6, A6H8J1, O49429, O80678, O80910, P12348, P55265, P94017, P97765, Q08B53, Q13434, Q32SG5, Q3T1I4, Q3TJZ6, Q3UMQ8, Q3UPH1, Q4R3M1, Q5F3N9, Q5FWT1, Q5R679, Q5XJA3, Q5Z8L1, Q66H68, Q6ICG8, Q6P870, Q7G6K7, Q7ZYB4, Q8AVN9, Q8LA32, Q8R478, Q8R4X3, Q93YP4, Q94JZ8, Q969T9, Q96M27, Q9C5P0, Q9C6S1, Q9D529, Q9FF15

Diamond homologs: M1BJF6, P97432, Q14596, Q3TT38, Q501R9, Q5BL31, Q5F3N9, Q5RC94, Q9H6K1, Q9SB64

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SMURF1	unknown	ILRUN	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

6 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	2
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1485 predictions. Top by Δscore:

Variant	Effect	Δscore
6:34646598:CA:C	donor_loss	1.0000
6:34646599:ACCT:A	donor_gain	1.0000
6:34646600:CCTC:C	donor_gain	1.0000
6:34646806:C:CT	acceptor_gain	1.0000
6:34646807:A:T	acceptor_gain	1.0000
6:34647433:C:A	donor_gain	1.0000
6:34654620:CTTA:C	donor_gain	1.0000
6:34654621:TTA:T	donor_loss	1.0000
6:34654622:TA:T	donor_loss	1.0000
6:34654623:A:AC	donor_gain	1.0000
6:34654623:AC:A	donor_gain	1.0000
6:34654624:C:CA	donor_gain	1.0000
6:34654624:CC:C	donor_gain	1.0000
6:34654624:CCA:C	donor_gain	1.0000
6:34654624:CCAG:C	donor_gain	1.0000
6:34654624:CCAGA:C	donor_gain	1.0000
6:34654775:GGTTC:G	acceptor_gain	1.0000
6:34654776:GTTC:G	acceptor_gain	1.0000
6:34654777:TTC:T	acceptor_gain	1.0000
6:34654778:TC:T	acceptor_gain	1.0000
6:34654779:CC:C	acceptor_gain	1.0000
6:34654780:C:CC	acceptor_gain	1.0000
6:34654780:C:T	acceptor_gain	1.0000
6:34654781:T:G	acceptor_loss	1.0000
6:34654782:A:AC	acceptor_gain	1.0000
6:34654782:A:C	acceptor_gain	1.0000
6:34696440:GCTCA:G	donor_loss	1.0000
6:34696441:CTCAC:C	donor_loss	1.0000
6:34696442:TCAC:T	donor_loss	1.0000
6:34696443:CA:C	donor_loss	1.0000

AlphaMissense

1972 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:34606896:A:G	W174R	1.000
6:34606896:A:T	W174R	1.000
6:34646603:C:A	G170V	1.000
6:34646603:C:T	G170E	1.000
6:34646604:C:G	G170R	1.000
6:34646604:C:T	G170R	1.000
6:34646633:C:G	R160P	1.000
6:34646635:C:A	W159C	1.000
6:34646635:C:G	W159C	1.000
6:34646636:C:G	W159S	1.000
6:34646637:A:G	W159R	1.000
6:34646637:A:T	W159R	1.000
6:34646643:C:G	G157R	1.000
6:34646643:C:T	G157R	1.000
6:34646668:G:C	S148R	1.000
6:34646668:G:T	S148R	1.000
6:34646670:T:G	S148R	1.000
6:34646681:A:T	V144D	1.000
6:34646768:A:G	L115P	1.000
6:34646768:A:T	L115H	1.000
6:34646785:C:A	W109C	1.000
6:34646785:C:G	W109C	1.000
6:34646787:A:G	W109R	1.000
6:34646787:A:T	W109R	1.000
6:34654639:C:G	R100P	1.000
6:34654641:C:A	W99C	1.000
6:34654641:C:G	W99C	1.000
6:34654642:C:G	W99S	1.000
6:34654643:A:G	W99R	1.000
6:34654643:A:T	W99R	1.000

dbSNP variants (sampled 300 via entrez): RS1000018719 (6:34635586 A>G), RS1000030053 (6:34631426 C>A), RS1000046463 (6:34644728 G>A,C), RS1000099588 (6:34604543 A>G), RS1000103682 (6:34622657 T>C), RS1000163018 (6:34629788 A>G), RS1000171823 (6:34673560 CATT>C), RS1000174315 (6:34688555 G>A), RS1000180333 (6:34671289 C>G,T), RS1000214843 (6:34587185 C>A), RS1000229661 (6:34694659 C>A), RS1000234433 (6:34671511 A>G,T), RS1000271472 (6:34654118 T>C), RS1000322227 (6:34621657 G>A,C), RS1000328324 (6:34593631 T>G)

Disease associations

OMIM: gene MIM:612217 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

75 associations (top):

Study	Trait	p-value
GCST000174_18	Height	4.000000e-12
GCST000372_16	Height	8.000000e-11
GCST000755_24	HDL cholesterol	4.000000e-09
GCST000760_43	Cholesterol, total	5.000000e-11
GCST001876_2	Pubertal anthropometrics	9.000000e-08
GCST001956_63	Height	8.000000e-13
GCST002221_12	Cholesterol, total	4.000000e-15
GCST002285_9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	1.000000e-06
GCST002783_262	Body mass index	3.000000e-10
GCST002783_36	Body mass index	2.000000e-09
GCST002783_617	Body mass index	2.000000e-10
GCST004146_25	Chronic lymphocytic leukemia	2.000000e-08
GCST004235_77	Total cholesterol levels	2.000000e-13
GCST004495_10	BMI (adjusted for smoking behaviour)	3.000000e-07
GCST004495_11	BMI (adjusted for smoking behaviour)	3.000000e-09
GCST004497_82	Body mass index (joint analysis main effects and smoking interaction)	3.000000e-09
GCST004497_83	Body mass index (joint analysis main effects and smoking interaction)	2.000000e-07
GCST004499_14	BMI in non-smokers	3.000000e-07
GCST004499_15	BMI in non-smokers	6.000000e-09
GCST005195_144	Coronary artery disease	2.000000e-11
GCST005196_96	Coronary artery disease	1.000000e-11
GCST006612_103	LDL cholesterol	3.000000e-08
GCST006802_28	Body mass index	2.000000e-09
GCST007293_46	Body fat distribution (arm fat ratio)	2.000000e-06
GCST007294_11	Body fat distribution (trunk fat ratio)	1.000000e-16
GCST007294_30	Body fat distribution (trunk fat ratio)	1.000000e-09
GCST007295_155	Body fat distribution (leg fat ratio)	1.000000e-24
GCST007295_161	Body fat distribution (leg fat ratio)	5.000000e-16
GCST008070_6	HDL cholesterol levels	4.000000e-07
GCST008075_181	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	8.000000e-10

EFO canonical traits (22, from GWAS)

EFO ID	Trait name
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004574	total cholesterol measurement
EFO:0001382	puberty
EFO:0004340	body mass index
EFO:0004318	smoking behavior
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004341	body fat distribution
EFO:0004329	alcohol drinking
EFO:0004338	body weight
EFO:0008039	BMI-adjusted hip circumference
EFO:0010100	multisite chronic pain
EFO:0000195	metabolic syndrome
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004918	age at diagnosis
EFO:0006935	thalamus volume
EFO:0004920	progression free survival
EFO:0007789	BMI-adjusted waist circumference
EFO:0004587	lymphocyte count
EFO:0005091	monocyte count
EFO:0004532	serum gamma-glutamyl transferase measurement
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	increases expression, decreases expression	2
Valproic Acid	increases expression	2
Cadmium Chloride	increases abundance, increases expression	2
FR900359	decreases phosphorylation	1
bisphenol A	increases methylation	1
afimoxifene	decreases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	increases expression	1
nickel sulfate	increases expression	1
dimethylarsinous acid	increases expression	1
abrine	increases expression	1
bisphenol S	decreases methylation	1
Fulvestrant	decreases expression	1
Vorinostat	decreases expression	1
Air Pollutants	increases expression, increases abundance	1
Benzo(a)pyrene	increases mutagenesis	1
Cadmium	increases abundance, increases expression	1
Selenium	increases expression	1
Thimerosal	decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Aflatoxin B1	decreases methylation	1
Lithium Chloride	increases expression	1
Copper Sulfate	increases expression	1
Acrylamide	increases expression	1
Raloxifene Hydrochloride	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1SX	HAP1 C6orf106 (-) 2	Cancer cell line	Male
CVCL_E1SY	HAP1 C6orf106 (-) 3	Cancer cell line	Male
CVCL_XM38	HAP1 C6orf106 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.